VivoSeq
Other

Bacteremia

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Bacteremia is an early-stage landscape with 0 programs across 1 company. The most active players are AM-Pharma.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

AM-Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Recruiting2 · 15%
Terminated2 · 15%
Unknown status1 · 8%
Not yet recruiting1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients
Recruiting·IInstituto Nacional de Cancerologia de Mexico·N/A·NCT06422533·226 enrolled
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT06650501·300 enrolled
An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures
Not yet recruiting·UUniversity of Santiago de Compostela·Phase 4·NCT06422221·150 enrolled
Evaluation of Bacteremia Epidemiology During the COVID Period in One French University Hospital
Completed·—·N/A·NCT05640349·4,200 enrolled
Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia
Completed·—·Phase 3·NCT01898338·167 enrolled
Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester
Completed·FFar Eastern Memorial Hospital·N/A·NCT03248973·1 enrolled
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
Completed·PPharmacia·Phase 3·NCT00002101·450 enrolled
Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia
Completed·PPhramongkutklao College of Medicine and Hospital·N/A·NCT03925402·427 enrolled
Bacteremia in Periodontal Patients
Completed·UUniversity of Taubate·Phase 4·NCT02215473·80 enrolled
Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.
Terminated·FFundación Pública Andaluza Progreso y Salud·Phase 3·NCT01875263·1 enrolled
An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures
Terminated·UUniversity of Santiago de Compostela·Phase 4·NCT02783404·40 enrolled
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis
Withdrawn·AAM-Pharma·Phase 1/2·NCT00509847
Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia
Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT05394298·284 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)